Ignacio Mata, PhD, is Assistant Professor at Cleveland Clinic Lerner College of Medicine. He hold a Bachelor of Science and PhD in Human/Medical Genetics from la Universidad de Oviedo in Asturias, Spain, and he received his PhD in Neurogenetics from Mayo Clinic. Dr. Mata's lab is working towards identifying and understanding the genes that play a role in those diseases that affect the brain (neurological disorders). These include the very well-known Parkinson’s disease (PD), but also other less common disorders such as a form of PD that presents with severe cognitive problems/dementia (PDD) and another type of dementia called Dementia with Lewy Bodies (DLB).
Recent Publications
- Chaparro-Solano, HM, Mata, IF. Authors' reply to "Comment on Chaparro-Solano et al.: 'Critical evaluation of the current landscape of pharmacogenomics in Parkinson's disease - What is missing? A systematic review'". Parkinsonism Relat Disord 2025; : 107804. PubMed PMID:40157818 .
- Lange, LM, Levine, K, Fox, SH, Marras, C, Ahmed, N, Kuznetsov, N, Vitale, D, Iwaki, H, Lohmann, K, Marsili, L et al.. The LRRK2 p.L1795F variant causes Parkinson's disease in the European population. NPJ Parkinsons Dis 2025; 11 (1): 58. PubMed PMID:40133296 PubMed Central PMC11937388.
- Tumas, V, Aureliano, MJ, Rieder, CRM, Schuh, AFS, Ferraz, HB, Borges, V, Soares, MC, Boone, DL, Silva, CCD, Costa, MC et al.. Modifiable risk factors associated with the risk of developing Parkinson's disease: a critical review. Arq Neuropsiquiatr 2025; 83 (3): 1-10. PubMed PMID:40107260 .
- Ramchandra, J, Inca-Martinez, M, Leal, TP, Chaparro-Solano, HM, Salim, A, Gatto, EM, Rojas, NG, Da Prat, G, Micheli, F, Santos-Lobato, BL et al.. Sex differences in the diagnosis latency of Parkinson's disease in Latin America. Parkinsonism Relat Disord 2025; 134 : 107344. PubMed PMID:40058072 .
- Gouveia, MH, Meeks, KAC, Borda, V, Leal, TP, Kehdy, FSG, Mogire, R, Doumatey, AP, Tarazona-Santos, E, Kittles, RA, Mata, IF et al.. Subcontinental Genetic Diversity in the All of Us Research Program: Implications for Biomedical Research. bioRxiv 2025; : . PubMed PMID:39829860 PubMed Central PMC11741438.
- Cisterna-Garcia, A, Bustos, BI, Bandres-Ciga, S, Leal, TP, Sarihan, EI, Jok, C, Krainc, D, Mata, IF, Lubbe, SJ, Botia, JA et al.. Genome-wide epistasis analysis reveals significant epistatic signals associated with Parkinson's disease risk. Brain 2024; : . PubMed PMID:39657708 .
- Chaparro-Solano, HM, Rivera Paz, M, Anis, S, Hockings, JK, Kundrick, A, Piccinin, CC, Assaedi, E, Saadatpour, L, Mata, IF. Critical evaluation of the current landscape of pharmacogenomics in Parkinson's disease - What is missing? A systematic review. Parkinsonism Relat Disord 2025; 130 : 107206. PubMed PMID:39551668 .
- Borda, V, Loesch, DP, Guo, B, Laboulaye, R, Veliz-Otani, D, French, JN, Leal, TP, Gogarten, SM, Ikpe, S, Gouveia, MH et al.. Genetics of Latin American Diversity Project: Insights into population genetics and association studies in admixed groups in the Americas. Cell Genom 2024; 4 (11): 100692. PubMed PMID:39486408 PubMed Central PMC11605695.
- Oas, H, Cook, L, Schwantes-An, TH, Walsh, LE, Wills, AM, Mata, IF, Nance, MA, Beck, JC, Naito, A, Marder, K et al.. Participant-reported personal utility of genetic testing for Parkinson's disease and interest in clinical trial participation. NPJ Parkinsons Dis 2024; 10 (1): 202. PubMed PMID:39455611 PubMed Central PMC11511990.
- Salim, A, Biswas, S, Sonneborn, C, Hogue, O, Hennessy, E, Mays, M, Suneja, A, Ahmed, Z, Mata, IF. Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ≥ 65 Years With Daily or Nondaily Migraine. Neurol Clin Pract 2025; 15 (1): e200373. PubMed PMID:39399553 PubMed Central PMC11464238.
